A review of the clinical use of anti-inflammatory therapies for reperfusion injury in myocardial infarction and stroke: Where do we go from here?

Current Opinion in Investigational Drugs

Volumn 7, Issue 3, 2006, Pages 229-242

  Kennedy, Thomas P ^a   Vinten Johansen, Jakob ^b  

^a UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adenosine; Anti inflammatory; Ischemia; Myocardial infarction; Reperfusion

Indexed keywords

ABCIXIMAB; ACETYLCYSTEINE; ADENOSINE; ALTEPLASE; ANTIINFLAMMATORY AGENT; CORTICOSTEROID; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; GLUCOCORTICOID RECEPTOR; GLUCOSE; HEPARIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOGLOBULIN G2A ANTIBODY; INTERCELLULAR ADHESION MOLECULE 1; INTERCELLULAR ADHESION MOLECULE 1 ANTIBODY; LOW MOLECULAR WEIGHT HEPARIN; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; PADGEM PROTEIN; PEXELIZUMAB; PLACEBO; RECOMBINANT PROTEIN; ROVELIZUMAB; TP 10; UK 279276; UNCLASSIFIED DRUG;

ANGIOCARDIOGRAPHY; ANTICOAGULATION; ANTIINFLAMMATORY ACTIVITY; BINDING AFFINITY; BLOOD CLOT LYSIS; BOLUS INJECTION; BRAIN HEMORRHAGE; CARDIOGENIC SHOCK; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COMPLEMENT ACTIVATION; CONGESTIVE HEART FAILURE; CORONARY ARTERY BYPASS SURGERY; DRUG DESIGN; DRUG EFFICACY; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG TOLERABILITY; HEART INFARCTION; HEART REINFARCTION; HUMAN; HYPERGLYCEMIA; MORTALITY; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION; REPERFUSION INJURY; REVIEW; RISK ASSESSMENT; RISK REDUCTION; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; ST SEGMENT ELEVATION; STATISTICAL SIGNIFICANCE; SURVIVAL; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT FAILURE; TREATMENT OUTCOME; UPREGULATION;

ADENOSINE; ANTI-INFLAMMATORY AGENTS; CEREBROVASCULAR ACCIDENT; CLINICAL TRIALS; HUMANS; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; VASODILATOR AGENTS;

EID: 33644943740     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (118)

1. Baxter GF: The neutrophil as a mediator of myocardial ischemia-reperfusion injury: Time to move on. Basic Res Cardiol (2002) 97(4)268-275.
2. Carden DL, Granger DN: Pathophysiology of ischaemia-reperfusion injury. J Pathol (2000) 190(3):255-266.
3. Sughrue ME, Mehra A, Connolly ES Jr, D'Ambrosio AL: Anti-adhesion molecule strategies as potential neuroprotective agents in cerebral ischemia: A critical review of the literature. Inflamm Res (2004) 53(10):497-508.
4. D'ambrosio AL, Pinsky DJ, Connolly ES: The role of the complement cascade in ischemia/reperfusion injury: Implications for neuroprotection. Mol Med (2001) 7(6):367-382.
5. Frijns CJ, Kappelle LJ: Inflammatory cell adhesion molecules in ischemic cerebrovascular disease. Stroke (2002) 33(8):2115-2122.
6. Nichols TC: NF-κB and reperfusion injury. Drug News Perspec (2004) 17(2):99-104.
7. Crack PJ, Taylor JM: Reactive oxygen species and the modulation of stroke. Free Rad Biol Med (2005) 38(11):1433-1444.
8. Hallenbeck JM: Inflammatory reactions at the blood-endothelial interface in acute stroke. Adv Neurol (1996) 71:281-297.
9. Kloner RA, Jennings RB: Consequences of brief ischemia: Stunning, preconditioning and their clinical implications. Part 1. Circulation (2001) 104(24):2981-2989.
10. Kloner RA, Jennings RB: Consequences of brief ischemia: Stunning, preconditioning and their clinical implications. Part 2. Circulation (2001) 104(25):3158-5167.
11. Piper HM, Abdallah Y, Schafer C: The first minutes of reperfusion: A window of opportunity for cardioprotection. Cardiovasc Res (2004) 61(3):365-371.
12. Halestrap AP, Clarke SJ, Javadov SA: Mitochondrial permeability transition pore opening during myocardial reperfusion - a target for cardioprotection. Cardiovasc Res (2004) 61(3):372-385.
13. Garcia-Dorado D, Rodriguez-Sinovas A, Ruiz-Meana M: Gap junction-mediated spread of cell injury and death during myocardial ischemia-reperfusion. Cardiovasc Res (2004) 61(3):386-401.
14. Schulz R, Kelm M, Heusch G: Nitric oxide in ischemia/reperfusion injury. Cardiovasc Res (2004) 61(3):402-413.
15. Eefting F, Rensing B, Wigman J, Pannekoek WJ, Liu WM, Cramer MJ, Lips DJ, Doevendans PA: Role of apoptosis in reperfuslon injury. Cardiovasc Res (2004) 61(3):414-426.
16. Armstrong SC: Protein kinase activation and myocardial ischemia/reperfusion injury. Cardiovasc Res (2004) 61(3):427-436.
17. Chi NC, Karliner JS: Molecular determinants of responses of myocardial ischemia/reperfusion injury: Focus on hypoxia-inducible and heat shock factors. Cardiovasc Res (2004) 61(3):437-447.
18. Hausenloy DJ, Yellon DM: New directions for protecting the heart against reperfusion injury: Targeting the reperfusion injury salvage kinase (RISK)-pathway. Cardiovasc Res (2004) 61(3):448-460.
19. Becker L: New concepts in reactive oxygen species and cardiovascular reperfusion physiology. Cardiovasc Res (2004) 61(3):461-470.
20. Szabo G, Liaudet L, Hagl S, Szabo C: Poly(ADP-ribose) polymerase activation in the reperfused myocardium. Cardiovasc Res (2004) 61(3):471-480.
21. Vinten-Johanssen J: Involvement of neutrophils in the pathogenesis of lethal myocardial reperfusion injury. Cardiovasc Res (2004) 61(3):481-497.
22. Gawaz M: Role of platelets In coronary thrombosis and reperfusion of ischemic myocardium. Cardiovasc Res (2004) 61(3):498-511.
23. Galinanes M, Fowler AG: Role of clinical pathologies in myocardial injury following ischaemia and reperfusion. Cardiovasc Res (2004) 61(3):512-521.
24. Murriel CL, Mochly-Rosen D: Opposing roles of δ and εPKC in cardiac ischemia and reperfusion: Targeting the apoptotic machinery. Archiv Biochem Biophys (2003) 420(2):246-254.
25. Riedemann NC, Ward PA: Complement in ischemia reperfusion Injury. Am J Pathol (2003) 162(2):363-367.
26. Dreyer WJ, Michael LH, West MS, Smith CW, Rothlein R, Rossen RD, Anderson DC, Entman ML: Neutrophil accumulation in ischemic canine myocardium. Insights into time course, distribution, and mechanisms of localization during early reperfusion. Circulation (1991) 84(1):400-411.
27. Lefer AM, Weyrich AS, Buerke M: Role of selectins, a new family of adhesion molecules, in ischaemia-reperfusion injury. Cardiovasc Res (1994) 28(3):289-294.
28. Weyrich AS, Buerke M, Albertine KH, Lefer AM: Time course of coronary vascular endothelial adhesion molecule expression during reperfusion of the ischemic feline myocardium. J Leuko Biol (1995) 57(1):45-55.
29. Rezkalla SH, Kloner RA: No-reflow phenomenon. Circulation (2002) 105(5):656-662.
30. del Zoppo GJ, Schmid-Schonbein GW, Mori E, Copeland BR, Chang CM: Polymorphonuclear leukocytes occlude capillaries following middle cerebral artery occlusion and reperfusion in baboons. Stroke (1991) 22(10):1276-1283.
31. de Bosscher K, Berghe VW, Haegeman G: The interplay between the glucocorticoid receptor and nuclear factor-κB or activator protein-1: Molecular mechanisms for gene repression. Endocrine Rev (2003) 24(4):488-522.
32. Hammerman H, Klonesr RA, Hale S, Schoen FJ, Braunwald E: Dose-dependent effects of short-term methylprednisolone on myocardial infarct extent, scar formation, and ventricular function. Circulation (1983) 68(2):446-452.
33. Silverman HS, Pfeifer MP: Relation between use of anti-inflammatory agents and left ventricular free well rupture during acute myocardial infarction. Am J Cardiol (1987) 59(4):363-364.
34. Cutroneo KR, Sterling KM Jr. How do glucocorticoids compare to oligo decoys as inhibitors of collagen synthesis and potential toxicity of these therapeutics? J Cell Biochem (2004) 92(1):6-15.
35. Baran KW, Nguyen M, McKendall GR, Lambrew CT, Dykstra G, Palmeri ST, Gibbons RJ, Borzak S, Sobel BE, Gourlay SG, Rundle AC et al for the LIMIT AMI Investigators: Double-blind, randomized trial of an anti-CD-18 antibody in conjunction with recombinant tissue plasminogen activator for acute myocardial infarction. Limitation of myocardial infarction following thrombolysis in acute myocardial infarction (LIMIT AMI) study. Circulation (2001) 104(23):2778-2783.
36. Faxon DP, Gibbons RJ, Chronos NA, Gurbel PA, Sheehan F, for the HALT-MI Investigators: The effect of blockade of the CD11/CD18 Integrin receptor on infarct size in patients with acute myocardial infarction treated with direct angioplasty: The result of the HALTMI study. J Am Col Cardiol (2002) 40(7):1199-1204.
37. Mahaffey KW, Puma JA, Barbagelata A, DiCarli MF, Leesar MA, Browne KF, Eisenbert PR, Bolli R, Casas AS, Molina-Viamonte V, Orlandi C et al: Adenosine as an adjunct to thrombolytic therapy for acute myocardial infarction. J Am Coll Cardiol (1999) 34(6):1711-1720.
38. Ross AM, Gibbons RJ, Stone GW, Kloner RA, Alexander RW, for the AMISTAD-II Investigators: A randomized, double-blinded, placebo-controlled multicenter trial of adenosine as an adjunct to reperfusion in the treatment of acute myocardial infarction (AMISTAD-II). J Am Coll Cardiol (2005) 45(11):1775-1780.
39. Simon D, Xu H, Ortlepp S, Rogers C, Rao NK: 7E2 monoclonal antibody directed against the platelet glycoprotein IIb/IIIa cross-reacts with the leukocyte integrin Mac-1 and blocks adhesion to fibrinogen and ICAM-1. Arterioscler Thromb Vasc Biol (1997) 17(3):528-535.
40. Mickeson JK, Nadir AM, Kleiman NS, Lakkis NM, Chow TW, Hughes BJ, Smith CW: Chimeric 7E3 Fab (ReoPro) decreases detectable CD11b on neutrophils from patients undergoing coronary angioplasty. J Am Coll Cardiol (1999) 33(1):97-106.
41. Coller BS: Potential non-glycoprotein IIb/IIIa effects of abciximab. Am Heart J (1999) 138(1 Pt 2)S1-5.
42. Neumann FJ, Blasini R, Schmitt C, Alt E, Dirschinger J, Gawaz M, Kastrati A, Schomig A: Effect of glycoprotein IIb/IIIa receptor blockade on recovery of coronary flow and left ventricular function after the placement of coronary-artery stents in acute myocardial infarction. Circulation (1998) 98(24):2895-2701.
43. Antoniucci D, Rodriguez A, Hempel A, Valenti R, Migliorini A, Vigo F, Parodi G, Fernandez-Pereira C, Moschi G, Bartorelli A, Santoro GM et al: A randomized trial comparing primary infarct artery stenting with or without abciximab in acute myocardial infarction. J Am Coll Cardiol (2003) 42(11): 1879-1885.
44. De Luca G, Suryapranata H, Stone GW, Antoniucci D, Tcheng JE, Neumann FJ, Van de Werf F, Antaman EM, Topol EJ: Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infarction. A meta-analysis of randomized trials. J Am Med Ass (2005) 293(14):1759-1765.
45. Wang L, Brown JR, Varki A, Esko JD: Heparin's anti-inflammatory effects require glucosamine 6-O-sulfation and are mediated by blockade of L- and P-selectins. J Clin Invest (2002) 110(1):127-136.
46. Koenig A, Norgard-Sumnicht K, Linhardt R, Varki A: Differential interactions of heparin and heparin sulfate glycosaminoglycans with the selectins. Implications for the use of unfractionated and low molecular weight heparins as therapeutic agents. J Clin Invest (1998) 101(4):877-889.
47. Peter K, Schwarz, M. Conradt C, Nordt T, Moser M, Kubler W, Bode C: Heparin inhibits ligand binding to the leukocyte integrin MAC-1 (CD11b/CD18). Circulation (1999) 100(14):1533-1539.
48. Salas A, Sans M, Soriano A, Reverter JC, Anderson DC, Pique JM, Panes J: Heparin attenuates TNF-α induced inflammatory response through a CD11b dependent mechanism. Gut (2000) 47(1):88-96.
49. Becker KJ: Anti-leukocyte antibodies: LeukArrest (Hu23F2G) and enlimomab (R6.5) in acute stroke. Curr Med Res Opin (2002) 18(Suppl 2):S18-S22.
50. Enlimomab Acute Stroke Trial Investigators: Use of anti-ICAM-1 therapy in ischemic stroke. Results of the enlimomab acute stroke trial. Neurology (2001) 57(8):1428-1434.
51. Zhang RL, Chopp M, Jiang N, Tang WX, Prostak J, Manning AM, Anderson DC: Anti-intercellular adhesion molecule-1 antibody reduces ischemic cell damage after transient but not permanent middle cerebral artery occlusion in the Wistar rat. Stroke (1995) 26(8):1438-1442.
52. Zanette EM, Roberti C, Mancini G, Pozzilli C, Bragoni M, Toni D: Spontaneous middle cerebral artery reperfusion in ischemic stroke. A follow-up study with franscranial Doppler. Stroke (1995) 26(3):430-433.
53. Schroff RW, Foon KA, Beatty SM, Oldham RK, Morgan AC Jr: Human anti-murine immunoglobulin responses in patients receiving monoclonal antibody therapy. Cancer Res (1985) 45(2):879-885.
54. Schneider D, Berrouschot J, Brandt T, Hacke W, Ferbert A Norris SH, Polmar SH, Schafer E: Safety, pharmacokinetics and biological activity of enlimomab (anti-ICAM-1 antibody): An open-label, dose escalation study in patients hospitalized for acute stroke. Eur Neurol (1998) 40(2):78-83.
55. Vuorte J, Lindsberg PJ, Kaste M, Meri S, Jansson S-E, Rothlein R, Repo H: Anti-ICAM-1 monoclonal antibody R6.5 (enlimomab) promotes activation of neutrophils in whole blood. J Immunol (1999) 162(4):2353-2357.
56. Furuya K, Takeda HJ, Azhar S, McCarron RM, Chen Y, Ruetzler CA, Wolcott KM, DeGraba TJ, Rothlein R, Hugli TE, del Zoppo GH, Hallenbeck JM: Examination of several potential mechanisms for the negative outcome in a clinical stroke trial of enlimomab, a murine anti-human intracellular adhesion molecule-1 antibody. A bedside-to-bench study. Stroke (2001) 32(11):2665-2674.
57. Lees KR, Diener H-C, Asplund K, Krams M, for the UK-279,276-301 Study Investigators: UK-279,276, a neutrophil inhibitory glycoprotein, in acute stroke. Tolerability and pharmacokinetics. Stroke (2003) 34(7):1704-1709.
58. Krams M, Lees KR, Hacke W, Grieve AP, Orgogozo J-M, Ford GA, for the ASTIN Study Investigators: Acute stroke therapy by inhibition of neutrophils (ASTIN). An adaptive dose-response study of UK-279,276 in acute ischemic stroke. Stroke (2003) 34(11):2543-2548.
59. Jiang N, Chopp M, Chahwala S: Neutrophil inhibitory factor treatment of focal cerebral ischemia in the rat. Brain Res (1998) 788(1-2):25-34.
60. Zhang L, Zhang ZG, Zhang RL, Lu M, Krams M, Chopp M: Effects of a selective CD11b/CD18 antagonist and recombinant tissue plasminogen activator treatment alone and in combination in a rat embolic model of stroke. Stroke (2003) 34(7):1790-1795.
61. Zhou W, Farrar CA, Abe K, Pratt JR, Marsh JE, Wang Y, Stahl GL, Sacks SH: Predominant role for 5b-9 in renal ischemia/reperfusion injury. J Clin Invest (2000) 105(10):1363-1371.
62. Fitch JC, Rollins S, Matis L, Alford B, Aranki S, Collard CD, Dewar M, Elefteriades J, Hines R, Kopf G, Kraker P et al: Pharmacology and biological efficacy of a recombinant, humanized, single-chain antibody C5 complement inhibitor in patients undergoing coronary artery bypass graft surgery with cardiopulmonary bypass. Circulation (1999) 100(25):2499-2506.
63. Mahaffey KW, Granger CB, Nicolau JC, Ruzyllo W, Weaver WD, Theroux P, Hochman JS, Filloon TG, Mojcik CF, Todaro TG, Armstrong PW for the COMPLY Investigators: Effect of pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to fibrinolysis in acute myocardial infarction. The COMPlement inhibition in myocardial infarction treated with throboLYtics (COMPLY) trial. Circulation (2003) 108(10):1176-1183.
64. Granger CB, Mahaffey KW, Weaver D, Theroux P, Hochman JS, Filloon TG, Rollins S, Todaro TG, Nicolau JC, Ruzyllo W, Armstrong PW for the COMMA Investigators: Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction. The COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) trial. Circulation (2003) 108(10):1184-1190.
65. Armstmng PW, Adams PX, Al-Khalidi HR, Hamm C, Holmes D, O'Neill W, Todaro TG, Vahanian A, Van de Werf F, Granger CB: Assessment of pexelizumab in acute myocardial infarction (APEX AMI): A multicenter, randomized, double-blind, parallel-group, placebo-controlled study of pexelizumab in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention. Am Heart J (2005) 149(3):402-407.
66. Verrier ED, Shernan SK, Taylor KM, Van de Werf F, Newman MF, Chen JC, Carrier M, Haverich A, Malloy KJ, Adams PX, Todaro TG at al for the PRIMO-CABG Investigators: Terminal complement blockade with pexelizumab during coronary artery bypass graft surgery requiring cardiopulmonary bypass. A randomized trial. J Am Med Ass (2004) 291(19):2319-2327.
67. Keshavjee S, Davis RD, Zamora MR, de Parrot M, Patterson GA: A randomized, placebo-controlled trial of complement inhibition in ischemia-reperfusion injury after lung transplantation in human beings. J Thorac Cardiovasc Surg (2005) 129(2):423-428.
68. Sobel BE, Bresnahan GF, Shell WE, Yoder RD: Estimation of infarct size in man and its relation to prognosis. Circulation (1972) 46(4):640-648.
69. Bleifeld W, Mathey D, Hanrath P, Buss H, Effert S: Infarct size estimated from serial serum creatine phosphokinase in relation to left ventricular hemodynamics. Circulation (1977) 55(2):303-311.
70. Grande P, Hansen BG, Christiansen C, Naestoft J: Acute myocardial infarct size estimated by serum CK-MB determinations: Clinical accuracy and prognostic relevance utilizing a practical modification of the isoenzyme approach. Am Heart J (1981) 101(5):582-586.
71. Zhao ZQ, Velez DA, Wang NP, Hewan-Lowa KO, Nakamura M, Guyton RA, Vinten-Johansen J: Progressively developed myocardial apoptotic cell death during the late phase of reperfusion. Apoptosis (2001) 6(4):279-290.
72. Stammberger U, Hamacher J, Hillinger S, Schmid RA: sCR1sLe ameliorates ischemia/reperfusion injury in experimental lung transplantation. J Thorac Cardiovasc Surg (2000) 120(6):1078-1084.
73. Schmidt RA, Hillinger S, Hamacher J, Stammberger U: TP2O is superior to TP10 in reducing ischemia/reperfuslon injury in rat lung grafts. Transplant Proc (2001) 33(1-2):948-949.
74. Vinten-Johansen J, Zhao Z-Q, Corvera JS, Morris CD, Budde JM, Thourani VH, Guyton RA: Adenosine in myocardial protection in on-pump and off-pump cardiac surgery. Ann Thorac Surg (2003) 75(2):S691-S699.
75. Minamino T, Kitakaze M, Asanuma H, Tomiyama Y, Shiraga M, Sato H, Ueda Y, Funaya H, Kuzuya T, Matsuzawa Y, Hori M: Endogenous adenosine inhibits P-selectin-dependent formation of coronary thromboemboli during hypoperfusion in dogs. J Clin Invest (1998) 101(8): 1643-1653.
76. Garratt KN, Holmes DDR, Molina-Viamonte V, Reeder GS, Hodge DO, Bailey KR, Lobl JK, Laudon DA, Gibbons RJ. Intravenous adenosine and lidocaine in patients with acute myocardial infarction. Am Heart J (1998) 136(2):196-204.
77. Tsao PS, Lefer AM: Time course and mechanism of endothelial dysfunction in isolated ischemic- and hypoxic-perfused rat hearts. Am J Physiol (1990) 259(6 Pt 2):H1860-H1666.
78. Kim H, Zhao Z-Q, Sun H-Y, Wang N-P, Corveera JS, Halkos ME, Karendi F, Guyton RA. Vinten-Johansen J: Postconditioning attenuates myocardial ischemia-reperfusion injury by inhibiting events in the early minutes of reperfusion. Cardiovasc Res (2004) 62(1):74-85.
79. Quintana M, Hjemdahl P, Sollevi A, Kahan T, Edner M, Rehnqvist N, Kjerr ES-C, Nasman P for the ATTACC Investigators: Left ventricular function and cardiovascular events following adjuvant therapy with adenosine in acute myocardial infarction treated with thrombolysis. Eur J Clin Pharmacol (2003) 59(1):1-9.
80. Kopecky SL, Aviles RJ, Bell MR, Lobl JK, Tipping D, Frommell G, Ramsey K, Holland AE, Midei M, Jain A, Kellett M, Gibbons RJ: A randomized, double-blinded, placebo-controlled, dose-ranging study measuring the effect of an adenosine agonist on infarct size reduction in patients undergoing primary percutaneous transluminal coronary angioplasty: The ADMIRE (AmP579 Delivery for Myocardial Infarction Reduction) study. Am Heart J (2003) 146(1):146-152.
81. Claeys MJ, Bosmans J, Veenstra L, Jorens P, De Raedt H, Vrints CJ: Determinants and prognostic implications of persistent ST-segment elevation after primary angioplasty for acute myocardial infarction: importance of microvascular reperfusion injury on clinical outcome. Circulation (1999) 99(15): 1972-1977.
82. Marzilla M, Orsini E, Marraccini P, Testa R: Beneficial effects of intracoronary adenosine as an adjunct to primary angioplasty in acute myocardial infarction. Circulation (2000) 101(18):2154-2159.
83. Assali A, Sdringola S, Ghani M, Denkats AE, Yepes A, Hanna G, Schroth G, Fujise K, Anderson HV, Smalling RW, Rosales OR: Intracoronary adenosine administered during percutaneous intervention in acute myocardial infarction and reduction in the incidence of 'no reflow' phenomenon. Catheter Cardiovasc Interv (2000) 51(1):27-31.
84. Claeys MJ, Bosmans J, De Ceuninck M, Beunis A, Vergauwen W, Vorlat A, Vrints CJ: Effect of intracoronary adenosine infusion during coronary intervention on myocardial reperfusion injury in patients with acute myocardial infarction. Am J Cardiol (2004) 94(1):9-13.
85. Kastrati A, Mehilli J, Dirschinger J, Schricke U, Neverve J, Pache J, Martinoff S, Neumann FJ, Nekolla S, Blasini R, Seyfarth M et al for the Stent versus Thrombolysis for Occluded Coronary Arteries in Patients Wth Acute Myocardial infarction (STOPAMI-2) Study Investigators. Myocardial salvage after coronary stenting plus abciximab versus fibrinolysis plus abciximab in patients with acute myocardial infarction: A randomised trial. Lancet (2002) 359(9310):920-925.
86. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group: Tissue plasminogen activator for acute ischemic stroke. N Engl J Med (1995) 333(24):1581-1587.
87. Hacke W, Brott T, Caplan L, Meier D, Fieschi C, von Kummer R, Donnan G, Heiss WD, Wahlgren NG, Spranger M, Boysen G, Marler JR: Thrombolysis in acute ischemic stroke: Controlled trials and clinical experience. Neurology(1999) 53(suppl 4):S3-S14.
88. Clark WM, Wissman S, Albers GW, Jhamandas JH, Madden KP, Hamilton S: Recombinant tissue-type plasminogen activator (alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: A randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke. J Am Med Ass (1999) 282(21):2019-2026.
89. Kent TA, Soukup VM, Fabian RH: Heterogeneity affecting outcome from acute stroke therapy. Making reperfusion worse. Stroke (2001) 32(10):2328-2327.
90. Gisselsson L, Smith ML, Siesjo BK: Hyperglycemia and focal brain ischemia. J Cereb Blood Flow Metab (1999) 19(3):288-297.
91. Kawai N, Keep RF, Betz AL: Hyperglycemia and the vascular effects of cerebral ischemia. Stroke (1997) 28(1):149-154.
92. Bruno A, Biller J, Adams HP Jr, Clarke WW, Woolson RF, Williams LS, Hansen MD: Acute blood glucose levels and outcome from ischemia stroke: Trial of ORG 10172 in Acute Stroke Treatment (TOAST) Investigators. Neurology (1999) 52(2):280-284.
93. Demchuk AM, Morgenstern LB, Krioeger DW, Linda Chi T, Hu W, Wein TH, Hardy RJ, Grotta JC, Buchan AM: Serum glucose level and diabetes predict tissue plasminogen activator-related intracerebral hemorrhage in acute ischemic stroke. Stroke (1999) 30(1):34-39.
94. Capes SE, Hunt D, Malmberg K, Gerstein HC: Stress hyperglycemia and increased risk of death after myocardial infarction in patients with and without diabetes: A systematic overview. Lancet (2000) 355(9206):773-778.
95. Wahab NN, Cowden EA, Pearce NJ, Gardner NJ, Merry H, Cox JL, for the ICONS Investigators: Is blood glucose an independent predictor of mortality in acute myocardial infarction in the thrombolytic era? J Am Coll Cardiol (2002) 40(10):1748-1754.
96. Iwakura K, Ito H, Ikushima M, Kawano S, Okamura A, Asano K. Kuroda T, Tanaka K, Masuyama T, Hori M, Fujii K: Association between hyperglycemia and the no-reflow phenomenon in patients with acute myocardial infarction. J Am Coll Cardiol (2003) 41(1):1-7.
97. Timmer JR, Ottervanger JP, de Boer MJ, Dambrink JH, Hoorntje JC, Gosselink AT, Surpapranata H, Zijlstra F, van't Hof AW for the Zwolle Myocardial Infarction Study Group: Hyperglycemia is an important predictor of impaired coronary flow before reperfusion therapy in ST-segment elevation myocardial infarction. J Am Coll Cardiol (2005) 45(7):999-1002.
98. Ishihara M, Inoue I, Kawagoe T, Shimatani Y, Kurisu S, Nishioka K, Umemura T, Nakamura S, Yoshida M: Impact of acute hyperglycemia on left ventricular function after reperfusion therapy in patients with a first anterior wall acute myocardial infarction. Am Heart J (2003) 146(4):674-678.
99. Schmidt AM, Yan SD, Yan SF, Stern DM: The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J Clin Invest (2001) 108(7):949-955.
100. Wautier JL, Schmidt AM: Protein glycation: A firm link to endothelial cell dysfunction. Circ Res (2004) 95(3):233-238.
101. Van den Berghe G, Wouters P, Weekers F, Verwaest C, Bruyninckx F, Schetz M, Vlasselaers D, Ferdinande P, Lauwers P, Bouillon R: Intensive insulin therapy in critically ill patients. N Engl J Med (2001) 345(19):1359-1367.
102. Lindsberg PJ, Grau AJ: Inflammation and infections as risk factors for ischemic stroke. Stroke (2003) 34(10):2518-2532.
103. Engstrom G, Stavenow L, Hedblad B, Lind P, Tyden P, Janzon L, Lindgarde F: Inflammation-sensitive plasma proteins and incidence of myocardial infarction in men with low cardiovascular risk. Arterioscler Thromb Vasc Biol (2003) 23(12):2247-2251.
104. Smeeth L, Thomas SL, Hall AJ, Hubbard R, Farrington P, Vallance P: Risk of myocardial infarction and stroke after acute infection or vaccination. N Engl J Med (2004) 351 (25):2611-2618.
105. 4 integrin and VCAM-1 in CD18-independent neutrophil migration across mouse cardiac endothelium. Circ Res (2002) 90(5):562-569.
106. Weiler JM, Edems RE, Linhardt RJ, Kapelanski DP: Heparin and modified heparin inhibit complement activation in vivo. J Immunol (1992) 148(10):3210-3215.
107. Thourani VH, Brar SS, Kennedy TP, Thornton LR, Watts JA, Ronson RS, Zhao Z-Q, Sturrock AL, Hoidal JR, Vinten-Johansen J: Nonanticoagulant heparin inhibits NF-kB activation and attenuates myocardial reperfusion injury. Am J Physiol Heart Circ Physiol (2000) 48:H2084-H2093.
108. Fryer A, Huang Y-C, Rao G, Jacoby D, Mancilla E, Whorton R, Piantadosi CA, Kennedy T, Hoidal J: Selective O-desulfation produces nonanticoagulant heparin that retains pharmacological activity in the lung. J Pharmacol Exp Ther (1997) 282(1):208-219.
109. Wright TC Jr, Pukac LA, Castellot JJ Jr, Karnovsky MJ, Levine RA, Kim-Park H-Y, Campisi J: Heparin suppresses the induction of c-fos and c-myc mRNA in murine fibroblasts by selective inhibition of a protein kinase C-dependent pathway. Proc Natl Acad Sci USA (1989) 88(9):3199-3203.
110. Pintus G, Tadolini B, Maioli M, Posadino AM, Gaspa L, Ventura C: Heparin down-regulates the phorbol ester-induced protein kinase C gene expression in human endothelial cells: Enzyme-mediated autoregulation of protein kinase C-α and -δ genes. FEBS Lett (1999) 449(2-3): 135-140.
111. Aoyagi K, Kuzure Y, Shahrzad S, Hirayama A, Nagase S, Ueda A: Inhibition by heparin of protein kinase C activation and hydroxyl radical generation in puromycin aminonucleoside treated isolated rat hepatocytes. Mol Cell Biochem (2003) 244(1-2):3-9.
112. Friedrichs GS, Kilgore KS, Manley PJ, Gralinski MR, Lucchesi BR: Effects of heparin and N-acetyl heparin on ischemia/reperfusion- induced alterations in myocardial function in the rabbit isolated heart. Circ Res (1994) 75(4):701-710.
113. Black SC, Gralinski MR, Friedrichs GS, Kilgoer KS, Driscoll EM, Lucchesi BR: Cardioprotective effects of heparin or N-acetylheparin in an in vivo model of myocardial ischaemic and reperfusion injury. Cardiovasc Res (1995) 29(5):629-636.
114. Mocco J, Choudhri T, Huang J, Harfeldt E, Efros L, Klingbeil C, Vexler V, Hall W, Zhang Y, Mack W, Popilskis S et al: HuEPSC7 as a humanized monoclonal anti-E/P-selectin neurovascular protective strategy in a blinded placebo-controlled trial of nonhuman primate stroke. Circ Res (2002) 91(10):907-914.
115. Sun LD, Tang YL, Xi WB, Zhang N, Zhang YZ: Study on the reperfusion rate of acute myocardial infarction affected by inspiring nitric oxide and resolving thrombus intravenously before admission. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue/Chinese Critical Care Medicine/Zhongguo Weizhongbing Jijiuyixue (2004) 16(3):169-171.
116. Acetadote®, acetylcysteine injection. Cumberland Pharmaceuticals Inc, Nashville, TN, USA (2004).
117. Sochman J: N-acetylcysteine in acute cardiology: 10 years later. What do we know and what would we like to know? J Am Cardiol (2002) 39(9):1422-1428.
118. Sochman J, Vrbska J, Musilova B, Rocek M, for the ISLAND Trial Group. Infarct Size Limitation: Acute N-acetylcystine Defense (ISLAND trial): Preliminary analysis and report after the first 30 patients. Clin Cardiol (1996) 19(2):94-100.